Kanser hücrelerinde miR-96-5p’nin AIFM3’ü düzenleyerek apoptoz ilişkili sinyali baskılaması
Öz
Anahtar Kelimeler
Destekleyen Kurum
Kaynakça
- 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
- 2. Dalmay T, Edwards D. MicroRNAs and the hallmarks of cancer. Oncogene. 2006;25(4):6170-5.
- 3. Yu J-J, Wu Y-X, Zhao F-J, Xia S-J. miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells. Med. Oncol. 2014;31(4):910.
- 4. Bao Y, Wang Y, Liu Y, Wang S, Wu B. MiR-96 expression in prostate cancer and its effect on the target gene regulation. Eur Rev Med Pharmacol Sci. 2017;21(20):4548-6.
- 5. Iwai N, Yasui K, Tomie A, Gen Y, Terasaki K, Kitaichi T, et al. Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. Int J Oncol. 2018;53(1):237-5.
- 6. Xie W, Sun F, Chen L, Cao X. miR-96 promotes breast cancer metastasis by suppressing MTSS1. Oncol Lett. 2018;15(3):3464-1.
- 7. Ress AL, Stiegelbauer V, Winter E, Schwarzenbacher D, Kiesslich T, Lax S, et al. MiR‐96‐5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Mol. Carcinog. 2015;54(11):1442-50.
- 8. Zheng A, Zhang L, Song X, Wang Y, Wei M, Jin F. Clinical implications of a novel prognostic factor AIFM3 in breast cancer patients. BMC cancer. 2019;19(1):451.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Klinik Tıp Bilimleri
Bölüm
Araştırma Makalesi
Yazarlar
Esra Bozgeyik
*
0000-0002-8726-3182
Türkiye
Yayımlanma Tarihi
20 Aralık 2020
Gönderilme Tarihi
22 Mart 2020
Kabul Tarihi
2 Ağustos 2020
Yayımlandığı Sayı
Yıl 2020 Cilt: 8 Sayı: 3